

Reference number(s)
6240-A

Initial Prior Authorization

Xphozah

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Xphozah	tenapanor

Indications

FDA-approved Indications

Xphozah is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Coverage Criteria

Chronic Kidney Disease (CKD)

Authorization may be granted when the requested drug is being prescribed to reduce serum phosphorus in an adult patient with chronic kidney disease (CKD) on dialysis as add-on therapy when ONE of the following criteria is met:

- The patient has experienced an inadequate treatment response to phosphate binders (e.g., PhosLo, Renvela, Velphoro, etc.).
- The patient has experienced an intolerance to any dose of phosphate binder therapy (e.g., PhosLo, Renvela, Velphoro, etc.).

Reference number(s)
6240-A

Duration of Approval (DOA)

- 6240-A: DOA: 12 months

References

1. Xphozah [package insert]. Waltham, MA: Ardelyx, Inc.; June 2025.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed October 3, 2025.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 10/3/2025).
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl.* 2017;7:1–59.